Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.90 |
| ▸ | CA12 | O43570 | 2/20 | 0.90 |
| ▸ | CA9 | Q16790 | 2/20 | 0.90 |
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | CA1 | P00915 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | IL1RN | P18510 | 1/20 | 0.63 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242888 | 0.95 | CA2 (1.00) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL7498033 | 0.93 | CA2 (0.83) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL1472241 | 0.86 | MEN1 (1.00) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL5230151 | 0.85 | CES1 (0.73) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL20472197 | 0.85 | CA2 (0.77) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL4941409 | 0.85 | CA2 (0.77) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL6577363 | 0.85 | CA2 (0.71) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL4574130 | 0.85 | CA2 (0.71) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL21247922 | 0.85 | CA2 (0.71) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL98037 | 0.85 | CA2 (0.71) | CA2CA12CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5734081-A | Arylthio compounds | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | claimed |
| CN-1155278-A | Arylthio compounds as antibacteral and antiviral agents | WARNER LAMBERT CO (US) | 1997-07-23 | — | — | CN | claimed |
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252841-B2 | Methods of inhibiting bacterial virulence and compounds relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2010-02-25 | — | — | US | disclosed |
| WO-2009088549-A2 | METHODS OF INHIBITING BACTERIAL VIRULENCE AND COMPOUNDS RELATING THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-07-16 | — | — | WO | disclosed |
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-7347879-B2 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'Oreál, S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20060005321-A1 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | L'OREAL S.A. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1568687-A1 | Sulphur-containing secondary para-Phenylenediamines, dying composition containing such para-phenylenediamines and methods using this composition and use | L'OREAL (FR) | 2005-08-31 | — | — | EP | disclosed |
| EP-0885205-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0885205-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| US-5780480-A | THROMBOLYTIC AGENTS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997031910-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060005321-A1 | Sulfur-containing secondary para-phenylenediamines dye compositions comprising such para-phenylenediamines, processes, and uses thereof | KRT18, CDC73, DSG1 | CA2 2100/4885CA12 856/4885CA9 549/4885 |
| US-20100048573-A1 | Methods of Inhibiting Bacterial Virulence and Compounds Relating Thereto | MMP8, SLC11A2, NFKBIA | CA2 2063/4885CA12 4360/4885CA9 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.